Cummings JL. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S15-20. PubMed Abstract
RELATED NEWSChicago: Trial Design Bedevils Search for New AD Drugs, Part 1Chicago: The Phase 2 Problem and the Way to a Surrogate, Part 2